Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Interest & Investment Income (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Interest & Investment Income for 14 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Interest & Investment Income fell 13.47% year-over-year to $2.4 million, compared with a TTM value of $9.1 million through Dec 2025, down 31.69%, and an annual FY2025 reading of $9.4 million, down 36.07% over the prior year.
  • Interest & Investment Income was $2.4 million for Q4 2025 at Enanta Pharmaceuticals, up from $2.1 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $4.7 million in Q3 2023 and bottomed at $255000.0 in Q1 2022.
  • Average Interest & Investment Income over 5 years is $2.3 million, with a median of $2.3 million recorded in 2025.
  • The sharpest move saw Interest & Investment Income surged 883.72% in 2023, then plummeted 39.83% in 2025.
  • Year by year, Interest & Investment Income stood at $258000.0 in 2021, then soared by 284.88% to $993000.0 in 2022, then surged by 332.83% to $4.3 million in 2023, then crashed by 34.88% to $2.8 million in 2024, then dropped by 13.47% to $2.4 million in 2025.
  • Business Quant data shows Interest & Investment Income for ENTA at $2.4 million in Q4 2025, $2.1 million in Q3 2025, and $2.3 million in Q2 2025.